

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/I98792973EDEN.html>

Date: April 2018

Pages: 55

Price: US\$ 3,500.00 (Single User License)

ID: I98792973EDEN

Abstracts

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H1 2018'; Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.

The report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H1 2018' outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 2, 3 and 1

respectively.

Report covers products from therapy areas Immunology, Oncology and Cardiovascular which include indications Melanoma, Systemic Lupus Erythematosus, Autoimmune Disorders, Blood Cancer, Diffuse Large B-Cell Lymphoma, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Metastatic Melanoma, Ovarian Cancer, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Solid Tumor and Stroke.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 2 Receptor

Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -
Overview

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -
Companies Involved in Therapeutics Development

Alkermes Plc

Celgene Corp

Medicenna Therapeutics Corp

Nektar Therapeutics

Philogen SpA

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug
Profiles

ALKS-4230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APT-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basiliximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basiliximab biobetter - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daclizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Darleukin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Daromun - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DEL-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Target NKG2D and IL2RA for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDNA-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKTR-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones

Featured News & Press Releases

Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders

Mar 09, 2018: EMA recommends immediate suspension and recall of s medicine

Zinbryta

Mar 02, 2018: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA (daclizumab) for Relapsing Multiple Sclerosis

Mar 02, 2018: EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders

Nov 10, 2017: EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage

Nov 08, 2017: Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer 32nd Annual Meeting

Nov 07, 2017: Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting

Oct 27, 2017: PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage

Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma

Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London

Jul 07, 2017: EMA restricts use of multiple sclerosis medicine Zinbryta

Jun 09, 2017: EMA reviews multiple sclerosis medicine Zinbryta

May 03, 2017: Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program

Apr 10, 2017: Biogen's Zinbryta accepted for use in NHS Scotland

Mar 27, 2017: Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Alkermes Plc, H1 2018

Pipeline by Celgene Corp, H1 2018

Pipeline by Medicenna Therapeutics Corp, H1 2018

Pipeline by Nektar Therapeutics, H1 2018

Pipeline by Philogen SpA, H1 2018

Dormant Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Alkermes Plc

Celgene Corp

Medicenna Therapeutics Corp

Nektar Therapeutics

Philogen SpA

I would like to order

Product name: Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/I98792973EDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I98792973EDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

